Skye Bioscience (SKYE) Q1 2026 earnings summary

Executive summary

• Lead candidate nimacimab is in Phase 2a clinical trials for obesity, showing suboptimal monotherapy efficacy but promising results in combination with semaglutide, including greater weight loss and improved body composition compared to semaglutide alone.

• Interim extension study data showed sustained and additional weight loss over 52 weeks for the combination arm, with a favorable safety profile and no serious adverse events.

• Initiated CBeyond Expansion Study (Part C) with Cohort 1 enrollment and scheduled safety review for potential progression to Cohort 2.

• Engaged Lilly Catalyze 360 for strategic guidance on nimacimab's target product profile and Phase 2b trial design.

• Completed all Q1 clinical milestones, including interim data, FDA meeting minutes, and compatibility studies.

Financial highlights

• Net loss for Q1 2026 was $12.5 million, compared to $11.1 million in Q1 2025.

• Research and development expenses increased to $7.9 million from $7.2 million year-over-year, driven by clinical trial and manufacturing costs.

• General and administrative expenses rose to $4.7 million from $4.6 million, mainly due to increased legal fees and stock-based compensation.

• Cash and cash equivalents plus short-term investments totaled $17.1 million as of March 31, 2026, down from $25.7 million at year-end 2025.

• Working capital was $8.2 million, with an accumulated deficit of $199.4 million.

Outlook and guidance

• Sufficient capital to fund operations through Q4 2026, excluding costs for a proposed Phase 2b study and related manufacturing.

• Continued losses and negative cash flows expected; additional capital will be needed to extend operations beyond Q4 2026.

• Topline data from the Phase 2a extension and expansion studies expected in Q3 and Q4 2026, respectively.

• Finalization of Phase 2b study design and operational readiness planned for Q4 2026.